Skip to main content
Fig. 7 | Stem Cell Research & Therapy

Fig. 7

From: Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma

Fig. 7

The relationship between TS score and immunotherapy response. A The TIDE score of each patient in high and low TS score groups. B Rate of response to immunotherapies predicted by TIDE in high or low TS score groups. C The count of patients in high or low TS score groups and response to immunotherapies true or false. Fisher’s exact test, p < 0.001. D Kaplan–Meier curves for low and high TS score groups in IMvigor 210 cohort. Log-rank test, p = 0.019. E Rate of clinical response (complete response [CR]/partial response [PR] and stable disease [SD]/progressive disease [PD]) to various immunotherapies in high or low TS score groups in the IMvigor 210 cohort. Fisher’s exact test, p = 0.0039. F Violin plot of TS score for PD, SD, PR, and CR groups in the IMvigor 210 cohort. G Kaplan–Meier curves for low and high TS score groups in the GSE78220 cohort. Log-rank test, p = 0.027. H Rate of clinical response (CR/PR and SD/PD) to various immunotherapies in high or low TS score groups in the GSE78220 cohort. Fisher’s exact test, p = 0.0128. I Violin plot of TS score for PD/SD and PR/CR groups in the GSE78220 cohort

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512